Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8767212 | 0.74 | PLAU (0.52) | LMNAMAPTCA2ALDH1A1NPC1 | |
| SCHEMBL1735291 | 0.74 | NOS3 (0.44) | NOS3NOS2NOS1ESR1LMNA | |
| SCHEMBL4607389 | 0.74 | NOS1 (0.44) | NOS1ESR1MAPTALOX15ESR2 | |
| SCHEMBL6385307 | 0.74 | NOS3 (0.44) | NOS3NOS1ESR1LMNACA1 | |
| SCHEMBL10672526 | 0.73 | TRPA1 (0.46) | ESR1KMT2AMEN1LMNACYP3A4 | |
| Hydroquinone SCHEMBL6071932 | 0.73 | LMNA (0.67) | ESR1KMT2AMEN1LMNACYP3A4 | |
| Hydroquinone SCHEMBL11180188 | 0.73 | LMNA (0.67) | ESR1KMT2AMEN1LMNACYP3A4 | |
| Hydroquinone SCHEMBL3095350 | 0.73 | LMNA (0.67) | ESR1KMT2AMEN1LMNACYP3A4 | |
| SCHEMBL53706 | 0.72 | — | — | |
| SCHEMBL2306420 | 0.72 | ALDH1A1 (0.46) | KMT2AMEN1LMNACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307501-A | Dihydrophenanthropyrrole compound, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-07-09 | — | — | CN | claimed |
| CN-118059113-A | Application of anemonin B4 derivative in preparation of medicine for preventing and treating psoriasis | 苏州大学 | 2024-05-24 | — | — | CN | claimed |
| CN-117567543-A | Anemonin B4 derivative and preparation method and application thereof | 苏州大学 | 2024-02-20 | — | — | CN | claimed |
| EP-2426139-A1 | CXCR4 antagonist and use thereof | Biokine Therapeutics Ltd. (IL) | 2012-03-07 | — | — | EP | claimed |
| US-8017585-B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2011-09-13 | — | — | US | claimed |
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2009-07-16 | — | — | US | claimed |
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-23 | — | — | US | claimed |
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| EP-1541585-A1 | CXCR4 ANTAGONIST AND USE THEREOF | Fujii, Nobutaka (JP) | 2005-06-15 | — | — | EP | claimed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | claimed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | claimed |
| US-20030055002-A1 | Dolastatin 10 derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | claimed |
| CN-118307501-A | Dihydrophenanthropyrrole compound, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-07-09 | — | — | CN | disclosed |
| CN-118126032-A | Fluorescent probe and preparation method and application thereof | 广州谱赛生物医学科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118059113-A | Application of anemonin B4 derivative in preparation of medicine for preventing and treating psoriasis | 苏州大学 | 2024-05-24 | — | — | CN | disclosed |
| US-6127538-A | HYDROXYALKYLATION OF A TRIAMINO TRIAZINE DERIVATIVE HAVING AT LEAST ONE REACTIVE NITROGEN BY REACTING WHILE HEATING WITH AN ALKANEDIOL OR ITS ADDUCT IN THE PRESENCE OF HYDROGEN AND A METAL CATALYST; BY-PRODUCT INHIBITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| WO-2000018759-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| EP-0882720-A1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | CXCR4, ACKR3, CXCR1 | NOS3 3130/4885NOS2 3301/4885NOS1 3289/4885 |
| US-20030055002-A1 | Dolastatin 10 derivatives | DAD1, DDOST, NPC1 | NOS3 2959/4885NOS2 3259/4885NOS1 2592/4885 |
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | CXCR4, ACKR3, CXCR1 | NOS3 3130/4885NOS2 3301/4885NOS1 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.